# Vontier Corp: financial statements, quarterly

VNT · NYSE · CIK 1786842 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vnt.md) · [Financials](/companies/vnt/financials.md) · [Filings](/companies/vnt/filings.md) · [Insiders](/companies/vnt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vnt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [765](/filings/0001786842-24-000074.md) | [789 d](/filings/0001628280-26-007648.md) | [756](/filings/0001786842-25-000028.md) | [696](/filings/0001786842-25-000065.md) | [750](/filings/0001628280-25-047448.md) | [777 d](/filings/0001628280-26-007648.md) | [741](/filings/0001628280-26-031945.md) | [774](/filings/0001628280-26-054180.md) | [753](/filings/0001628280-25-047448.md) | [809 d](/filings/0001628280-26-007648.md) | [751](/filings/0001628280-26-031945.md) | [757](/filings/0001628280-26-054180.md) |
| Cost of revenue | $m | [406](/filings/0001786842-24-000074.md) | not reported | [384](/filings/0001786842-25-000028.md) | [361](/filings/0001786842-25-000065.md) | [396](/filings/0001628280-25-047448.md) | not reported | [391](/filings/0001628280-26-031945.md) | [403](/filings/0001628280-26-054180.md) | [396](/filings/0001628280-25-047448.md) | not reported | [398](/filings/0001628280-26-031945.md) | [392](/filings/0001628280-26-054180.md) |
| Gross profit | $m | [359](/filings/0001786842-23-000074.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [39.1](/filings/0001786842-24-000074.md) | [43.1 d](/filings/0001628280-26-007648.md) | [44.5](/filings/0001786842-25-000028.md) | [45.1](/filings/0001786842-25-000065.md) | [45.7](/filings/0001628280-25-047448.md) | [42.4 d](/filings/0001628280-26-007648.md) | [40.2](/filings/0001628280-26-031945.md) | [47.5](/filings/0001628280-26-054180.md) | [44.4](/filings/0001628280-25-047448.md) | [43.6 d](/filings/0001628280-26-007648.md) | [41.4](/filings/0001628280-26-031945.md) | [35.1](/filings/0001628280-26-054180.md) |
| Selling, general and administrative | $m | [157](/filings/0001786842-24-000074.md) | [162 d](/filings/0001628280-26-007648.md) | [165](/filings/0001786842-25-000028.md) | [156](/filings/0001786842-25-000065.md) | [157](/filings/0001628280-25-047448.md) | [151 d](/filings/0001628280-26-007648.md) | [160](/filings/0001628280-26-031945.md) | [167](/filings/0001628280-26-054180.md) | [151](/filings/0001628280-25-047448.md) | [161 d](/filings/0001628280-26-007648.md) | [159](/filings/0001628280-26-031945.md) | [168](/filings/0001628280-26-054180.md) |
| Operating income | $m | [143](/filings/0001786842-24-000074.md) | [146 d](/filings/0001628280-26-007648.md) | [142](/filings/0001786842-25-000028.md) | [114](/filings/0001786842-25-000065.md) | [132](/filings/0001628280-25-047448.md) | [149 d](/filings/0001628280-26-007648.md) | [130](/filings/0001628280-26-031945.md) | [136](/filings/0001628280-26-054180.md) | [142](/filings/0001628280-25-047448.md) | [153 d](/filings/0001628280-26-007648.md) | [135](/filings/0001628280-26-031945.md) | [147](/filings/0001628280-26-054180.md) |
| Income tax | $m | [29.3](/filings/0001786842-24-000074.md) | [18.2 d](/filings/0001628280-26-007648.md) | [26.0](/filings/0001786842-25-000028.md) | [21.9](/filings/0001786842-25-000065.md) | [20.5](/filings/0001628280-25-047448.md) | [7.0 d](/filings/0001628280-26-007648.md) | [23.2](/filings/0001628280-26-031945.md) | [28.8](/filings/0001628280-26-054180.md) | [33.2](/filings/0001628280-25-047448.md) | [16.9 d](/filings/0001628280-26-007648.md) | [26.8](/filings/0001628280-26-031945.md) | [16.4](/filings/0001628280-26-054180.md) |
| Net income | $m | [90.6](/filings/0001786842-24-000074.md) | [106 d](/filings/0001628280-26-007648.md) | [137](/filings/0001628280-25-047448.md) | [70.1](/filings/0001628280-25-047448.md) | [91.8](/filings/0001628280-25-047448.md) | [124 d](/filings/0001628280-26-007648.md) | [87.9](/filings/0001628280-26-054180.md) | [91.9](/filings/0001628280-26-054180.md) | [103](/filings/0001628280-25-047448.md) | [124 d](/filings/0001628280-26-007648.md) | [94.3](/filings/0001628280-26-054180.md) | [27.4](/filings/0001628280-26-054180.md) |
| Diluted EPS | $ per share | [0.58](/filings/0001786842-24-000074.md) | not reported | [0.88](/filings/0001786842-25-000028.md) | [0.45](/filings/0001786842-25-000065.md) | [0.60](/filings/0001628280-25-047448.md) | not reported | [0.59](/filings/0001628280-26-031945.md) | [0.62](/filings/0001628280-26-054180.md) | [0.70](/filings/0001628280-25-047448.md) | not reported | [0.66](/filings/0001628280-26-031945.md) | [0.20](/filings/0001628280-26-054180.md) |
| Basic EPS | $ per share | [0.59](/filings/0001786842-24-000074.md) | not reported | [0.89](/filings/0001786842-25-000028.md) | [0.45](/filings/0001786842-25-000065.md) | [0.60](/filings/0001628280-25-047448.md) | not reported | [0.59](/filings/0001628280-26-031945.md) | [0.62](/filings/0001628280-26-054180.md) | [0.70](/filings/0001628280-25-047448.md) | not reported | [0.67](/filings/0001628280-26-031945.md) | [0.20](/filings/0001628280-26-054180.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-29) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [264](/filings/0001786842-23-000074.md) | [341](/filings/0001786842-25-000008.md) | [406](/filings/0001786842-24-000033.md) | [331](/filings/0001786842-24-000065.md) | [331](/filings/0001786842-24-000074.md) | [356](/filings/0001628280-26-007648.md) | [334](/filings/0001786842-25-000028.md) | [364](/filings/0001786842-25-000065.md) | [434](/filings/0001628280-25-047448.md) | [492](/filings/0001628280-26-054180.md) | [234](/filings/0001628280-26-031945.md) | [266](/filings/0001628280-26-054180.md) |
| Current assets | $m | [1,303](/filings/0001786842-23-000074.md) | [1,333](/filings/0001786842-25-000008.md) | [1,361](/filings/0001786842-24-000033.md) | [1,293](/filings/0001786842-24-000065.md) | [1,343](/filings/0001786842-24-000074.md) | [1,370](/filings/0001628280-26-007648.md) | [1,370](/filings/0001786842-25-000028.md) | [1,418](/filings/0001786842-25-000065.md) | [1,525](/filings/0001628280-25-047448.md) | [1,492](/filings/0001628280-26-054180.md) | [1,267](/filings/0001628280-26-031945.md) | [1,280](/filings/0001628280-26-054180.md) |
| Total assets | $m | [4,222](/filings/0001786842-23-000074.md) | [4,294](/filings/0001786842-25-000008.md) | [4,306](/filings/0001786842-24-000033.md) | [4,236](/filings/0001786842-24-000065.md) | [4,307](/filings/0001786842-24-000074.md) | [4,311](/filings/0001628280-26-007648.md) | [4,293](/filings/0001786842-25-000028.md) | [4,376](/filings/0001786842-25-000065.md) | [4,380](/filings/0001628280-25-047448.md) | [4,369](/filings/0001628280-26-054180.md) | [4,131](/filings/0001628280-26-031945.md) | [4,031](/filings/0001628280-26-054180.md) |
| Current liabilities | $m | [868](/filings/0001786842-23-000074.md) | [955](/filings/0001786842-25-000008.md) | [865](/filings/0001786842-24-000033.md) | [767](/filings/0001786842-24-000065.md) | [818](/filings/0001786842-24-000074.md) | [909](/filings/0001628280-26-007648.md) | [843](/filings/0001786842-25-000028.md) | [1,311](/filings/0001786842-25-000065.md) | [1,291](/filings/0001628280-25-047448.md) | [1,289](/filings/0001628280-26-054180.md) | [1,031](/filings/0001628280-26-031945.md) | [1,022](/filings/0001628280-26-054180.md) |
| Total liabilities | $m | [3,457](/filings/0001786842-23-000074.md) | [3,398](/filings/0001786842-25-000008.md) | [3,313](/filings/0001786842-24-000033.md) | [3,212](/filings/0001786842-24-000065.md) | [3,264](/filings/0001786842-24-000074.md) | [3,251](/filings/0001628280-26-007648.md) | [3,187](/filings/0001786842-25-000028.md) | [3,167](/filings/0001786842-25-000065.md) | [3,141](/filings/0001628280-25-047448.md) | [3,118](/filings/0001628280-26-054180.md) | [2,866](/filings/0001628280-26-031945.md) | [2,832](/filings/0001628280-26-054180.md) |
| Long-term debt | $m | [2,348](/filings/0001786842-23-000074.md) | [2,189](/filings/0001786842-25-000008.md) | [2,190](/filings/0001786842-24-000033.md) | [2,190](/filings/0001786842-24-000065.md) | [2,191](/filings/0001786842-24-000074.md) | [2,092](/filings/0001628280-26-007648.md) | [2,092](/filings/0001786842-25-000028.md) | [1,594](/filings/0001786842-25-000065.md) | [1,594](/filings/0001628280-25-047448.md) | [1,594](/filings/0001628280-26-054180.md) | [1,595](/filings/0001628280-26-031945.md) | [1,595](/filings/0001628280-26-054180.md) |
| Current portion of debt | $m | not reported | [100](/filings/0001786842-25-000008.md) | [50.0](/filings/0001786842-24-000033.md) | [0.0](/filings/0001786842-24-000065.md) | [0.0](/filings/0001786842-24-000074.md) | [50.0](/filings/0001628280-26-007648.md) | [0.0](/filings/0001786842-25-000028.md) | [499](/filings/0001786842-25-000065.md) | [500](/filings/0001628280-25-047448.md) | [500](/filings/0001628280-26-054180.md) | [0.0](/filings/0001628280-26-031945.md) | [0.0](/filings/0001628280-26-054180.md) |
| Short-term borrowings | $m | [6.3](/filings/0001786842-23-000074.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [2.4](/filings/0001628280-26-054180.md) | [306](/filings/0001628280-26-031945.md) | [305](/filings/0001628280-26-054180.md) |
| Shareholders' equity | $m | [760](/filings/0001786842-23-000074.md) | [890](/filings/0001786842-25-000008.md) | [985](/filings/0001786842-24-000033.md) | [1,016](/filings/0001786842-24-000065.md) | [1,035](/filings/0001786842-24-000074.md) | [1,051](/filings/0001628280-26-007648.md) | [1,096](/filings/0001786842-25-000028.md) | [1,202](/filings/0001786842-25-000065.md) | [1,233](/filings/0001628280-25-047448.md) | [1,244](/filings/0001628280-26-054180.md) | [1,259](/filings/0001628280-26-031945.md) | [1,193](/filings/0001628280-26-054180.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [132 d](/filings/0001786842-24-000074.md) | [165 d](/filings/0001628280-26-007648.md) | [91.5](/filings/0001786842-25-000028.md) | [46.1 d](/filings/0001786842-25-000065.md) | [122 d](/filings/0001628280-25-047448.md) | [168 d](/filings/0001628280-26-007648.md) | [110](/filings/0001628280-26-031945.md) | [100 d](/filings/0001628280-26-054180.md) | [111 d](/filings/0001628280-25-047448.md) | [190 d](/filings/0001628280-26-007648.md) | [46.5](/filings/0001628280-26-031945.md) | [116 d](/filings/0001628280-26-054180.md) |
| Capital expenditure | $m | [17.4 d](/filings/0001786842-24-000074.md) | [16.6 d](/filings/0001628280-26-007648.md) | [20.2](/filings/0001786842-25-000028.md) | [23.8 d](/filings/0001786842-25-000065.md) | [18.6 d](/filings/0001628280-25-047448.md) | [20.1 d](/filings/0001628280-26-007648.md) | [17.7](/filings/0001628280-26-031945.md) | [16.7 d](/filings/0001628280-26-054180.md) | [20.2 d](/filings/0001628280-25-047448.md) | [15.3 d](/filings/0001628280-26-007648.md) | [21.7](/filings/0001628280-26-031945.md) | [21.4 d](/filings/0001628280-26-054180.md) |
| Dividends paid | $m | [3.9 d](/filings/0001786842-24-000074.md) | [3.8 d](/filings/0001628280-26-007648.md) | [3.9](/filings/0001786842-25-000028.md) | [3.8 d](/filings/0001786842-25-000065.md) | [3.8 d](/filings/0001628280-25-047448.md) | [3.7 d](/filings/0001628280-26-007648.md) | [3.7](/filings/0001628280-26-031945.md) | [3.7 d](/filings/0001628280-26-054180.md) | [3.7 d](/filings/0001628280-25-047448.md) | [3.6 d](/filings/0001628280-26-007648.md) | [3.5](/filings/0001628280-26-031945.md) | [3.6 d](/filings/0001628280-26-054180.md) |
| Share repurchases | $m | [11.6 d](/filings/0001786842-24-000074.md) | [13.1 d](/filings/0001628280-26-007648.md) | [21.6](/filings/0001786842-25-000028.md) | [38.1 d](/filings/0001786842-25-000065.md) | [105 d](/filings/0001628280-25-047448.md) | [60.1 d](/filings/0001628280-26-007648.md) | [55.0](/filings/0001628280-26-031945.md) | [50.1 d](/filings/0001628280-26-054180.md) | [70.0 d](/filings/0001628280-25-047448.md) | [125 d](/filings/0001628280-26-007648.md) | [70.0](/filings/0001628280-26-031945.md) | [130 d](/filings/0001628280-26-054180.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [159](/filings/0001786842-23-000074.md) | [156](/filings/0001786842-24-000033.md) | [156](/filings/0001786842-24-000065.md) | [156](/filings/0001786842-24-000074.md) | [155](/filings/0001786842-25-000028.md) | [156](/filings/0001786842-25-000065.md) | [153](/filings/0001628280-25-047448.md) | [150](/filings/0001628280-26-031945.md) | [148](/filings/0001628280-26-054180.md) | [147](/filings/0001628280-25-047448.md) | [143](/filings/0001628280-26-031945.md) | [140](/filings/0001628280-26-054180.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 135,200,000 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054180.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.